This trial will evaluate a non-invasive brain imaging technique QUTE-CE MRI and validate the method with first-in-human studies.

This trial will evaluate a non-invasive brain imaging technique QUTE-CE MRI using Ferumoxytol as a contrast agent, and validate the method with first-in-human studies. Subjects who are already scheduled to receive ferumoxytol infusion will undergo MRI scans after the infusion. The ferumoxytol infusion itself is not a part of the study. The project will provide brain angiograms and establish a human cerebrovascular atlas that will enable future quantitative diagnosis of cerebrovascular abnormalities by revealing abnormal regions of the brain that characterize disease, a tool which doesn't currently exist, and which could lead to many exciting discoveries and clinical applications in neurology.

Inclusion Criteria:

• Between the ages of 18 to 80;
• Able to understand written consent document and HIPAA authorization prior to initiation of study related procedures.

Exclusion Criteria:

• Known allergy to ferumoxytol or any intravenous iron preparation;
• Iron saturation above the upper limit of normal;
• Individuals with a contraindication to MRI, such as the presence of metallic prostheses or implanted metal device (e.g., infusion pump, defibrillator);
• Individuals with known clinical conditions that may lead to iron overload including hemochromatosis, cirrhosis, or sickle cell disease;
• Individuals with any serious medical condition that the investigator believes may place them at increased risk for an adverse event.

Patients with iron deficiency anemia already scheduled to receive ferumoxytol infusion for iron replacement therapy.